Spire Healthcare Group (LON:SPI – Get Free Report) had its price target raised by analysts at JPMorgan Chase & Co. from GBX 249 ($3.12) to GBX 280 ($3.50) in a research report issued to clients and investors on Friday, Digital Look reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 27.43% from the company’s previous close.
Separately, Barclays increased their target price on shares of Spire Healthcare Group from GBX 300 ($3.75) to GBX 305 ($3.82) and gave the company an “overweight” rating in a research report on Friday.
Spire Healthcare Group Stock Performance
About Spire Healthcare Group
Spire Healthcare Group plc, together with its subsidiaries, owns and operates private hospitals and clinics. It offers various treatments in the areas of allergy and infectious diseases, blood tests, bones and joints, bowel treatments, breast screening, cancer investigations and treatments, cosmetic surgery, cyst removal, and dental surgery, as well as ear, nose, and throat treatments.
- Five stocks we like better than Spire Healthcare Group
- Best Stocks Under $10.00
- Institutions and Insiders Are Gobbling Up Shares of HASI
- How to Invest in the Entertainment Industry
- Investors Betting On Triple-Digit Sales Growth At Las Vegas Sands
- Large Cap Stock Definition and How to Invest
- 3 Reasons Why AMD Might Breakout Higher
Receive News & Ratings for Spire Healthcare Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spire Healthcare Group and related companies with MarketBeat.com's FREE daily email newsletter.